✦ LIBER ✦

Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study

✍ Scribed by Varga, Cindy; Holcroft, Christina; Kezouh, Abbas; Bucatel, Serghei; Johnson, Nathalie; Petrogiannis-Haliotis, Tina; Assouline, Sarit

Book ID: 120921017
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 256 KB
Volume: 55
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2013.790968

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of rituximab on treatment outcome

Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis

✍ Linda Lee; Michael Crump; Sara Khor; Jeffrey S. Hoch; Jin Luo; Karen Bremner; Mu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Comparison of outcomes after allogeneic

Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma

✍ Kohei Tada; Sung-Won Kim; Yoshitaka Asakura; Nobuhiro Hiramoto; Kimikazu Yakushi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 923 KB

Comparison of clinical outcome after aut

Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma

✍ Sohn, B S; Park, I; Kim, E K; Yoon, D H; Lee, S S; Kang, B W; Jang, G; Choi, Y H 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 203 KB

R-CHOP-14 in patients with diffuse large

R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study

✍ Antonio Rueda; Pilar Sabin; Juli Rifá; Marta Llanos; José Gómez-Codina; Francisc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

## Abstract Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B‐cell lymphoma (DLBCL). These studies prompt

Real world costs and cost-effectiveness

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

✍ Sara Khor,Jaclyn Beca,Murray Krahn,David Hodgson,Linda Lee,Michael Crump… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 952 KB

Clinical outcomes and prognostic factors

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

✍ Ho-Young Yhim; Hye Jin Kang; Yoon Hee Choi; Seok Jin Kim; Won Seog Kim; Yee Soo 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 939 KB